Navigation Links
Argos Therapeutics' Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
Date:6/1/2011

DURHAM, N.C., June 1, 2011 /PRNewswire/ -- Argos Therapeutics announced today that its Arcelis™ immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib demonstrated a strong immunologic response that correlated to improved clinical outcomes. The Phase 2 combination study in newly diagnosed, metastatic RCC patients with unfavorable prognosis demonstrated decreases in T regulatory cells, along with a concurrent expansion of CD28+memory cytotoxic T lymphocytes (CTL). Results will be presented by Dr. Robert Figlin, director of the Division of Hematology/Oncology at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, in a poster and a discussion session at 8 a.m. CDT, and noon CDT, respectively, Saturday, June 4, 2011, at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

The study is the first to demonstrate the combined immunologic and clinical effects of AGS-003, or any active immunotherapy, with sunitinib. Most patients experienced reversal of baseline tumor-induced immunosuppression and showed improved progression-free survival (PFS) compared to the expected PFS with sunitinib alone in an unfavorable risk, metastatic RCC patient population. Assessment of immunodynamicsusing multiparametric flow cytometry was performed on peripheral blood mononuclear cells isolated from blood draws collected prior to treatment and after treatment with AGS-003 during combination administration with sunitinib. Nine of 11 patients with PFS of >10 months demonstrated CTL population increases whereas two of four patients with PFS <10 months showed increases in this specific CTL population. Updates on the correlation between prolonged PFS and CTL expansion will be presented during ASCO.

"The study provides initial evidence that AGS-003
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
2. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
3. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
4. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
5. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
6. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
7. Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
8. Reportlinker Adds Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017
9. Cell Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Rule
10. Amicus Therapeutics to Present at Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011
11. Reportlinker Adds Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 CVS Health Corporation (NYSE: CVS ... May 1, 2015, at 8:30 a.m. (EDT) with analysts ... An audio webcast of the conference call ... of the CVS Health website for all interested parties. ... webcast will be archived and available on the web ...
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/dl9gbg/admetoxicology ) ... - Global Strategic Business Report" report to their ... for ADME-Toxicology Testing in US$ Million by the following ... The report provides separate comprehensive analytics for ... Japan , Europe , ...
(Date:4/17/2015)... 2015  Trovagene, Inc., (NASDAQ:  TROV) a developer ... data presented at the 2015 European Lung Cancer ... Monitoring ℠ (PCM) platform outperformed tissue biopsy ... T790M mutations in metastatic lung cancer patients. ... Mutation in Urinary Circulating Tumor DNA from Metastatic ...
Breaking Medicine Technology:ADME-Toxicology Testing (In-Vivo, & In-Vitro) Market - Global Strategic Business Report 2015: Pharma Industry Renews Focus on Cost Optimization 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4
(Date:4/18/2015)... The Residential Senior Care Franchises ... years. The industry, which provides residential and personal-care services ... for themselves, has boomed on account of the aging ... seniors with memory impairment. As a result, IBISWorld expects ... 4.1% to $1.9 billion over the five years to ...
(Date:4/18/2015)... Carinsurancehints.com has released a new blog post explaining how to ... against fire damage. , Clients can now find auto ... is set intentionally on fire. This type of damages can ... things. , It is possible to compare the best ... , in just a few minutes. Clients should always ...
(Date:4/18/2015)... has released a new blog post explaining how to ... Clients can review important auto insurance quotes online, by ... advantages for clients who need affordable financial security for ... coverage for their vehicles can purchase a policy at ... agencies offer important discounts and drivers can learn more ...
(Date:4/18/2015)... New York, New York (PRWEB) April 18, 2015 ... http://www.consumerinjurylawyers.com/depuy-pinnacle/lawsuit ) filed on behalf of individuals who ... hip replacement system continue to move forward in the ... an Order dated April 10th, the Court has amended ... joinder of unrelated cases. Among other things, the new ...
(Date:4/18/2015)... Aureus Medical Group (web: aureusmedical.com), a ... jobs, has announced that it will participate as ... Association Annual Conference to be held May 1-2, ... , The SCAPTA Annual Conference offers educational ... services. , Representatives from Aureus Medical’s ...
Breaking Medicine News(10 mins):Health News:Residential Senior Care Franchises in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Residential Senior Care Franchises in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Online Auto Insurance Quotes For Plans That Cover Fire Damages! 2Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2
... finds , THURSDAY, June 11 (HealthDay News) -- Mad cow ... somehow goes astray and deprives the healthy brain cells of ... considered a prion disease because it has been found to ... is found on the surface of many cells -- including ...
... ... media age. , ... (Vocus) June 11, 2009 -- From cyberbullying and violent video games to social networking and ... To help parents navigate this new and changing landscape, the Center on Media and ...
... of the crime in cancer are guilty of the initiation and ... disease, a team led by scientists at The University of Texas ... Cancer Cell . "We have a smoking gun" that ... that makes them are abnormally expressed in many types of cancer, ...
... Wii may help treat symptoms of Parkinson,s disease, including ... Parkinson,s disease is a degenerative disease that impairs ... game console, which simulates various sports and activities, could ... found additional benefits as well. "The Wii allows ...
... fifth most common malignancy worldwide and the third leading ... been associated with HCC. However, the relationship between type ... the effects of antidiabetic therapy on HCC risk have ... led by Dr. Valter Donadon from Pordenone Hospital addressed ...
... common cancers in China. Although the association between the ... the relation between smoking, alcohol drinking, family history of ... still remains uncertain. So it is important to investigate ... sporadic colorectal cancer. A research team led by ...
Cached Medicine News:Health News:Protein Branded As Culprit in Mad Cow Disease 2Health News:Center on Media and Child Health Launches "Ask the Mediatrician" 2Health News:Center on Media and Child Health Launches "Ask the Mediatrician" 3Health News:Researchers identify 4 new targets for breast cancer 2Health News:Wii-hab may enhance Parkinson's treatment 2
... intended for the quantitative determination of prolactin ... in the diagnosis and treatment of disorders ... BioCheck Prolactin Quantitative Test is based on ... immunosorbent assay. The assay system utilized sheep ...
Prolactin Radioimmunoassay...
... a polypeptide hormone secreted in significant amounts ... placenta. Prolactin, in synergy with estrogen, plays ... and maintenance of mammary gland growth and ... may have effects on cell growth in ...
... ADVIA Centaur delivers a ... It provides the flexibility to ... system, now and in the ... a comprehensive disease-focused menu of ...
Medicine Products: